The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid arthritis (RA) market increasingly crowded. The expected launch of Galapagos / Gilead’s JAK inhibitor filgotinib, R-Pharm’s IL-6 inhibitor olokizumab, and GlaxoSmithKline’s otilimab over the next few years will further fragment the market. Drug developers will undoubtedly face increasing challenges to gain favorable formulary positioning and physician uptake. In such scenarios, market access decisions for these therapies will play a key role in influencing rheumatologists’ prescribing behaviors in RA.
Geography: United States.
Primary research: Survey of 96 U.S. rheumatologists and 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).
Key drugs covered: Actemra, Cimzia, Enbrel, filgotinib, Humira, infliximab, Kevzara, olokizumab, Olumiant, Orencia, otilimab, Rinvoq, Rituxan, Simponi, Xeljanz.
Reimbursement and contracting.
Access and prescribing.
Opportunities and challenges for emerging therapies.
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.